Life Sciences
Life Sciences Caption
Successful commercialization of pharmaceutical and biotechnology products depends on maximizing...
Pharma & Biotechnology
Life Pharma & Biotechnology
Commercial success for pharmaceutical and biotechnology products requires companies...
Pharmaceutical Law Group PC
Pharmaceutical Law Group focuses on providing legal advice to pharmaceutical, biotechnology, and medical device companies on matters at the intersection of FDA regulation and intellectual property. Pharmaceutical law Group has extensive experience in advising companies on market protection strategies, data exclusivity, Orange Book listings and other Hatch-Waxman Act procedures, patent term restoration, competition from ANDA and 505(b)(2) applicants, pediatric exclusivity, orphan drug exclusivity, follow-on biologics, and similar matters that arise in the contexts of transactions, licensing, and due diligence.
Gregory J. Glover, MD, Principal, Pharmaceutical Law Group PC
Gregory Glover, a registered patent attorney and non-practicing physician, is one of the nation’s experts on the complex interaction of food and drug laws and intellectual property. Greg represents life sciences companies, investors, and trade associations on strategic product development issues, including: market protection analyses based on intellectual property laws, FDA regulations, and patent portfolio evaluations. Greg has also testified on behalf of the research-based pharmaceutical industry before committees of both houses of Congress on legislative matters affecting market protection for pharmaceutical, biotechnology and medical device products. In addition, Greg has made presentations on behalf of research-based companies on market protection issues before the Food and Drug Administration, the Federal Trade Commission, and the Department of Justice.

Greg leads the activities of Pharmaceutical Law Group along with Project Consultants, who provide additional legal and business expertise.
News & Events
“Drugs and Biologics: The Issues and Challenges for the Industry,”
The University of Florida, College of Pharmacy, Pharmaceutical Outcomes and Policy Seminar,
October 22, 2011
“Life Cycle Management Considerations for the Biosimilars Market,”
American Conference Institute, 12th Annual Maximizing Patent Life Cycles,
October 4, 2011 (Panel Moderator)
Boosting Innovation in Antibiotics, National Law Journal
December 1, 2008
The Influence of Market Exclusivity
August 3, 2007